Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Change in Receivables (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Change in Receivables for 5 consecutive years, with -$896000.0 as the latest value for Q4 2019.

  • Quarterly Change in Receivables changed N/A to -$896000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2019, changed N/A year-over-year, with the annual reading at $1.8 million for FY2019, 41.47% down from the prior year.
  • Change in Receivables hit -$896000.0 in Q4 2019 for Aptevo Therapeutics, down from $540000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.1 million in Q2 2016 to a low of -$5.9 million in Q4 2015.
  • Historically, Change in Receivables has averaged $330117.6 across 5 years, with a median of $957000.0 in 2018.
  • Biggest five-year swings in Change in Receivables: tumbled 657.73% in 2016 and later soared 878.05% in 2018.
  • Year by year, Change in Receivables stood at -$5.9 million in 2015, then skyrocketed by 122.57% to $1.3 million in 2016, then rose by 21.74% to $1.6 million in 2017, then skyrocketed by 151.77% to $4.1 million in 2018, then tumbled by 122.06% to -$896000.0 in 2019.
  • Business Quant data shows Change in Receivables for APVO at -$896000.0 in Q4 2019, $540000.0 in Q3 2019, and $1.6 million in Q2 2019.